News | March 01, 2025
Healthcare Triangle announces $15.2 million PIPE offering
The PIPE offering consists of 36,190,476 units
The PIPE offering consists of 36,190,476 units
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Comprehensive clinical development programs being initiated for each investigational candidate
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
Subscribe To Our Newsletter & Stay Updated
